Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.
The firm said that the new funds will enable it to build on the continued commercial expansion of its first product, PredictSure IBD, in the coming months.
The firm had revenues of $6.32 billion in Q2, up 4 percent from $6.08 billion last year and just beating the average Wall Street estimate of $6.3 billion.
The test could potentially enable labs to bring resistance testing in house, rather than send testing out to Canada's National Microbiology Laboratory.
The firm is applying the isolation tool in cellular therapy for oral cancer by administering a biomarker via bioengineered exosomes to reverse cancer progression.
Filamentous prophages turned up in a significant proportion of cystic fibrosis Pseudomonas aeruginosa lung infections, particular in older patients and drug-resistant cases.
Addenbrooke' Hospital will manage and facilitate the fulfillment orders of the firm's PredictSure IBD orders, as well as receive and process all samples.
Researchers detected distinct antibiotic resistance patterns in untreated urban wastewater samples from northern and southern Europe.
The company is developing dedicated product lines for next-generation sequencing that incorporate a thermal cycler capable of 35-minute PCR.
The company's assay relies on a set of 15 methylation and microRNA markers to determine whether a woman has breast cancer.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.